ReviewMagma (New York, N.Y.)2022
The role of MRI in prostate cancer: current and future directions.
Review in Magma (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 61 citations in OpenAlex.
- Trial
- Imaging Efficacy of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Artificial intelligence advances in cystoscopy and imaging for bladder cancer: a narrative review.The Canadian journal of urology · 2026Review
- Improving membranous urethral length measurements on prostate MRI: a comparison of online training methods.European radiology · 2026Article
- Vitamin D and adverse pathologic features in patients undergoing radical prostatectomy in the contemporary magnetic resonance imaging-guided management era.BJUI compass · 2026Article
- Importance of the Quality of Annotation: Impact of Simulated Inter-Observer Variability on Deep Neural Network Automated Segmentation Model Performance.Bioengineering (Basel, Switzerland) · 2026Article
- Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.Cancers · 2026Review
- MRI-Derived Biomarkers and Radiomic Signatures for Early, Dose-Dependent Evaluation of Prostate Cancer Radiotherapy: An Exploratory Study.Journal of imaging · 2026Article
- Article
- Prostate Cancer Screening in Contemporary Era: PSA-Based Testing and Risk-Adapted Approaches.Cancers · 2026Review
- Prostate imaging reporting and data system version 2.1 as a predictor of clinically significant and aggressive prostate cancer: a radical prostatectomy-validated study.Translational andrology and urology · 2026Article
- An AI-Based Radiomics Model Using MRI ADC Maps for Accurate Prediction of Advanced Prostate Cancer Progression.Current oncology (Toronto, Ont.) · 2026Article
- ADC-based radiomics for risk stratification in prostate cancer: a clinical decision support study.Frontiers in oncology · 2026Article
- Recent advances in artificial intelligence-assisted medical imaging education.Frontiers in medicine · 2026Review
- Article
- AI in Prostate MRI: A Task-Based Review.Journal of the Korean Society of Radiology · 2025Review
- Combining MRI radiomics, hypoxia gene signature score and clinical variables for prediction of biochemical recurrence-free survival after radiotherapy in prostate cancer.La Radiologia medica · 2025Article
- Wide-field quantitative micro-elastography of freshly excised human prostate.Biomedical optics express · 2025Article
- Comparison of mpMRI andDiagnostics (Basel, Switzerland) · 2025Article
- Mitigating bias in prostate cancer diagnosis using synthetic data for improved AI driven Gleason grading.NPJ precision oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
There has been an increasing role of magnetic resonance imaging (MRI) in the management of prostate cancer. MRI already plays an essential role in the detection and staging, with the introduction of functional MRI sequences. Recent advancements in radiomics and artificial intelligence are being tested to potentially improve detection, assessment of aggressiveness, and provide usefulness as a prognostic marker. MRI can improve pretreatment risk stratification and therefore selection of and follow-up of patients for active surveillance. MRI can also assist in guiding targeted biopsy, treatment planning and follow-up after treatment to assess local recurrence. MRI has gained importance in the evaluation of metastatic disease with emerging technology including whole-body MRI and integrated positron emission tomography/MRI, allowing for not only better detection but also quantification. The main goal of this article is to review the most recent advances on MRI in prostate cancer and provide insights into its potential clinical roles from the radiologist's perspective. In each of the sections, specific roles of MRI tailored to each clinical setting are discussed along with its strengths and weakness including already established material related to MRI and the introduction of recent advancements on MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.